Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of busulfan, cyclophosphamide, and fludarabine.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Busulfan; Cyclophosphamide; Fludarabine
- Indications Haematological malignancies
- Focus Therapeutic Use
- 06 Apr 2012 Biomarkers information updated
- 05 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Apr 2012 Planned number of patients changed from 50 to 55 as reported by ClinicalTrials.gov.